University of Iowa Health Care researchers are part of a team that received a five-year, $16 million grant from the National Institutes of Health to lead a study on the cause of idiopathic intracranial hypertension and test a potential new treatment.

Idiopathic intracranial hypertension is a disorder of elevated pressure inside the cranium, or skull, with an unknown cause. Untreated, it may cause blindness.

The investigation will involve 40 study sites Michael Wall, MD, professor of neurology and ophthalmology, will direct an investigational treatment trial for patients newly diagnosed with the condition.

In addition to a treatment trial, Markus Kuehn, PhD, assistant professor of ophthalmology and visual sciences, and Edwin Stone, MD, PhD, professor of ophthalmology and visual sciences and a Howard Hughes Medical Institute investigator, will lead a genetics study that will evaluate genetic risk factors for idiopathic intracranial hypertension.

The project aims to provide evidence-based guidelines for treatment of the condition, reveal mechanisms of this therapy and lead to an understanding of the cause of the disorder. The research teams will collaborate through the Neuro-ophthalmology Research Disease Investigator Consortium.

For more information:

Michael Wall, MD

Markus Kuehn, PhD

Edwin Stone, MD, PhD